![Artist's depiction of an ultrapotent COVID-19 vaccine candidate in which 60 pieces of a coronavirus protein (red) decorate nanoparticles (blue and white). The vaccine candidate was designed using methods developed at the UW Medicine Institute for Protein Design. The molecular structure of the vaccine roughly mimics that of a virus, which may account for its enhanced ability to provoke an immune response [Credit: Ian Haydon/ UW Medicine Institute for Protein Design].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Nanoparticle-covid-19-vaccine-300x278.jpg)
![Artist's depiction of an ultrapotent COVID-19 vaccine candidate in which 60 pieces of a coronavirus protein (red) decorate nanoparticles (blue and white). The vaccine candidate was designed using methods developed at the UW Medicine Institute for Protein Design. The molecular structure of the vaccine roughly mimics that of a virus, which may account for its enhanced ability to provoke an immune response [Credit: Ian Haydon/ UW Medicine Institute for Protein Design].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Nanoparticle-covid-19-vaccine.jpg)
news
Highly potent nanoparticle COVID-19 vaccine designed using computer
Developers suggest that the potency, stability and manufacturability of the nanoparticle vaccine candidate could enable vaccination against COVID-19 on a global scale.
List view / Grid view
Formulation
article
Stepping up metformin production: a case study
This article describes how researchers stepped up metformin tablet production from a pilot scale coater to three industrial scale equipment lines.
article
How a global network provides a genuine advantage
When a client gets an opportunity to expand rapidly, it takes a global partner to pull it off without a hitch.
article
Science and risk-based specification setting for excipients
Reducing unnecessary regulatory burden relating to excipients is important for any pharmaceutical manufacturer. In this article, Sunil Kumar Nataraj, Bastiaan Dickhoff and Kalyan Janjanam discuss a rational basis for controlling and specifying conflicting excipient attributes to avoid potentially tedious and complex regulatory processes.
article
Approval of regulatory starting materials
There are significant interpretational differences between the European Medicines Agency (EMA) and US Food and Drug Administration (FDA)’s guidance on active pharmaceutical ingredient (API) starting materials. In this article, Dave Elder explores the ambiguity in guidance from both agencies and addresses why industry struggles to identify and justify starting materials…
news
First-in-human trial to study remestemcel-L as Crohn’s disease therapy launched
A Phase I clinical trial of remestemcel-L delivered by an endoscope to patients with Crohn’s disease and ulcerative colitis has commenced.
article
Expert view: High viscosity, high volume biologics call for new delivery device designs
The increasing use of subcutaneous administration stems from the significant advances in biological drug development, as well as the rising trend of self-administration.
news
Chemspec Digital 2020: pave the way for the recovery of the fine and speciality chemicals industry
Hosted online from 11 – 12 November, Chemspec Digital 2020 provides an interactive networking event for the fine and speciality chemicals community. From all over the world, industry experts will have the opportunity to meet, conduct business, discover innovative substances and learn about the latest trends and developments.
video
On-demand webinar: BioPhorum raw materials risk assessments
Introduction to BioPhorum (BPOG) raw materials risk assessments tool and an overview on risk assessment regulations for raw materials.
webinar
Liquid-filled hard capsules: A flexible tool for rapid access to the clinic with poorly soluble and/or highly potent compounds
21 October 2020 | By Lonza Pharma & Biotech
Watch our on-demand webinar to learn about liquid-filled hard capsule technology has a proven record for addressing complex active pharmaceutical ingredient (API) formulation challenges, including bioavailability enhancement.
news
Inhaled antibody treatment for COVID-19 shows success in pre-clinical trials
Researchers have developed a monoclonal antibody called AR-711 that is highly neutralising against COVID-19 in an inhaled formulation.
news
COVID-19 pandemic to heighten sales of pharmaceutical spray drying
A new report has predicted that the COVID-19 pandemic will drive demand for pharmaceutical spray drying, boosting the market.
whitepaper
Whitepaper: Streamlining pharma operations in the wake of COVID-19
Find out how to streamline your pharmaceutical operations in a COVID-19 environment.
news
First patient dosed in COVID-19 vaccine tablet clinical trial
A Phase I clinical trial to test VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate, has been initiated with the first patient dosed.
news
Team enhances bioavailability of simvastatin with mucoadhesive buccal films
Researchers have shown that mucoadhesive buccal films containing simvastatin inclusion complex and drug mixed micelles can improve the drug's bioavailability.
